Abstract
Aim:
Polysaccharide sulfate (PSS) is a new type of heparinoid synthesized with alginic acid as the basic material and then by chemical introduction of effective groups. Although PSS is successfully applied in ischemic cardio-cerebrovascular disease, its effect on cardiac function after ischemia/reperfusion (I/R) injury has previously not been investigated. The aim of the present study was to investigate whether PSS can protect the heart from I/R injury and the underlying mechanism of protection.
Methods:
Isolated rat hearts were perfused (Langendorff) and subjected to 20 min global ischemia followed by 60 min reperfusion with Kreb's Henseleit solution or PSS (0.3–100 mg/L). Myocardial contractile function was continuously recorded. Creatine kinase (CK) and lactate dehydrogenase (LDH) leakage were measured. Tumor necrosis factor-α (TNF-α) expression in cardiomyocytes was investigated. Western blot analysis for extracellular regulated kinases (ERKs), c-jun amino-terminal kinase (JNKs) and p38 mitogen-activated protein kinase (MAPK) activity was performed.
Results:
After I/R, cardiac contractility decreased, CK and LDH levels increased in the coronary effluent, and TNF-α expression increased in cardiomyocytes. PSS administration at concentrations of 1–30 mg/L improved cardiac contractility, reduced CK and LDH release and inhibited TNF-α production. Phosphorylated-p38MAPK (p-p38MAPK) and p-p54/p46-JNK increased in I/R rat hearts but diminished in PSS (1–30 mg/L) treated hearts. P-p44/p42-ERK levels were unchanged. In contrast, high concentrations of PSS (100 mg/L) had adverse effects that caused a worsening of heart function.
Conclusion:
PSS has dose-dependent cardioprotective effects on the rat heart after I/R injury. The beneficial effects may be mediated through normalization of the activity of p38 MAPK and JNK pathways as well as controlling the level of TNF-α expression.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Han ZY, Wang QA, Zeng GJ . Clinical and laboratory observations on polysaccharide sulphate (PSS) in 282 cases of ischemic cerebrovascular disease. Chin Med J (Engl) 1991; 104: 562–6.
You Y, Xie HJ, Zhang YF, Liu ZJ, Yang QD . Effect of the P-selectin expression on cerebral blood flow in rats with cerebral ischemia-reperfusion injury. J Apoplexy Nervous Dis 2005; 22: 155–7.
Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR . Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995; 29: 629–36.
Gralinski MR, Driscoll EM, Friedrichs GS, DeNardis MR, Lucchesi BR . Reduction of myocardial necrosis after glycosaminoglycan administration: effects of a single intravenous administration of heparin or N-acetylheparin 2 hours before regional ischemia and reperfusion. J Cardiovasc Pharmacol Ther 1996; 1: 219–28.
Park JL, Kilgore KS, Naylor KB, Booth EA, Murphy KL, Lucchesi BR . N-Acetylheparin pretreatment reduces infarct size in the rabbit. Pharmacology 1999; 58: 120–31.
Zhao MM, Li Z, Teng Z, Zhao JS, Yu XH, Watanabe Y, et al. Repeated oral treatment with polysaccharide sulfate reduces insulin resistance and dyslipidemia in diabetic dyslipidemic rat model. Yao Xue Xue Bao 2007; 42: 488–91.
Xie SQ, Du GJ, Ji BS, Lin HH, Xu QT, Hu XJ, et al. Effect of polysaccharide sulfate on brain environment after focal cerebral ischemia reperfusion in rat and its promotion for growth of the chick embryonic dorsal root ganglion. Chin Pharm J 2006; 41: 33–6.
Wu K, Qian WM, Wu P . Therapeutic effects of intravenous polysaccharide sulfate in treatment of coronary heart disease. Chin J Clin Pharmacol Ther 1996; 1: 31–3.
Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996; 79: 162–73.
Maulik N, Yoshida T, Zu YL, Sato M, Banerjee A, Das DK . Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol 1998; 275: H1857–64.
Liao P, Wang SQ, Wang S, Zheng M, Zheng M, Zhang SJ, et al. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 2002; 90: 190–6.
Wang M, Sankula R, Tsai BM, Meldrum KK, Turrentine M, March KL, et al. P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression. Shock 2004; 21: 170–4.
Lewis TS, Shapiro PS, Ahn NG . Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49–139.
Kyriakis JM, Avruch J . Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 1996; 271: 24313–6.
Wang X, Martindale JL, Liu Y, Holbrook NJ . The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 1998; 333 (Pt 2): 291–300.
Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM . The role of the complement system in ischemia-reperfusion injury. Shock 2004; 21: 401–9.
Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999; 27: 1309–18.
Maass DL, White J, Horton JW . IL-1beta and IL-6 act synergistically with TNF-alpha to alter cardiac contractile function after burn trauma. Shock 2002; 18: 360–6.
Sakamoto A, Matsumura J, Mii S, Gotoh Y, Ogawa R . A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production. Shock 2004; 22: 76–81.
Wright JG, Kerr JC, Valeri CR, Hobson RW 2nd . Heparin decreases ischemia-reperfusion injury in isolated canine gracilis model. Arch Surg 1988; 123: 470–2.
Marshall CJ . Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179–85.
Sugden PH, Bogoyevitch MA . Intracellular signalling through protein kinases in the heart. Cardiovasc Res 1995; 30: 478–92.
Liao S, Porter D, Scott A, Newman G, Doetschman T, Schultz Jel J . The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. J Mol Cell. Cardiol 2007; 42: 106–20.
Milano G, Morel S, Bonny C, Samaja M, von Segesser LK, Nicod P, et al. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol 2007; 292: H1828–35.
Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 2002; 53: 414–22.
Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, et al. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem 2003; 242: 173–80.
Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL . Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96: 1042–52.
Odeh M . Tumor necrosis factor-alpha as a myocardial depressant substance. Int J Cardiol 1993; 42: 231–8.
Meldrum DR . Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577–95.
Gurevitch J, Frolkis I, Yuhas Y, Paz Y, Matsa M, Mohr R, et al. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol 1996; 28: 247–52.
Stambe C, Atkins RC, Hill PA, Nikolic-Paterson DJ . Activation and cellular localization of the p38 and JNK MAPK pathways in rat crescentic glomerulonephritis. Kidney Int 2003; 64: 2121–32.
Paz Y, Frolkis I, Pevni D, Shapira I, Yuhas Y, Iaina A, et al. Effect of tumor necrosis factor-alpha on endothelial and inducible nitric oxide synthase messenger ribonucleic acid expression and nitric oxide synthesis in ischemic and nonischemic isolated rat heart. J Am Coll Cardiol 2003; 42: 1299–305.
Liu S, Wang CB, Guo SB, Yan YJ . The primary approach to untoward reactions and rational application of polysaccharide sulphate. Chin J Marine Drugs 1992; 11: 17–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, Y., Hu, Sj., Li, L. et al. Cardioprotection by polysaccharide sulfate against ischemia/reperfusion injury in isolated rat hearts. Acta Pharmacol Sin 30, 54–60 (2009). https://doi.org/10.1038/aps.2008.12
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2008.12
Keywords
This article is cited by
-
The liver protection of propylene glycol alginate sodium sulfate preconditioning against ischemia reperfusion injury: focusing MAPK pathway activity
Scientific Reports (2017)
-
Protective Effect of Apigenin on Ischemia/Reperfusion Injury of the Isolated Rat Heart
Cardiovascular Toxicology (2015)
-
Cardioprotective Effect of Rhizomes of Acorus gramineus Against Isoproterenol-Induced Cardiac Damage in Pigs
Cardiovascular Toxicology (2014)
-
The Elevated Serum S100A8/A9 During Acute Myocardial Infarction Is Not of Cardiac Myocyte Origin
Inflammation (2012)
-
Influence of ginsenoside-Re against myocardial infarction in isolated heart
Molecular & Cellular Toxicology (2011)
